Lixisenatide studies: 116 papers with results
Page 2 of 3
Lixisenatide has 428 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.
- Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.
Becker RH · Diabetes/metabolism research and reviews · 2015
Randomized controlled trial · 12 results
- Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.
Farngren J · Diabetes care · 2016
Randomized controlled trial · 9 results
- Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes.
Jones KL · Diabetes, obesity & metabolism · 2019
Randomized controlled trial · 8 results
- Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution.
Jalleh R · Nutrients · 2020
Randomized controlled trial · 14 results
- The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial.
Juel CTB · Diabetologia · 2020
Randomized controlled trial · 11 results
- Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance.
Whyte MB · The Journal of clinical endocrinology and metabolism · 2019
Randomized controlled trial · 10 results
- Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.
Becker RH · Diabetes, obesity & metabolism · 2014
Randomized controlled trial · 11 results
- Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial.
Davies MJ · Diabetes, obesity & metabolism · 2019
Randomized controlled trial · 5 results
- Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day.
Ahrén B · Journal of diabetes and its complications · 2014
Randomized controlled trial · 8 results
- The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control.
Gautier T · Journal of diabetes science and technology · 2021
Randomized controlled trial · 4 results
- Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study.
Seino Y · Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2015
Non-randomized trial · 10 results
- Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.
Davies MJ · Diabetes, obesity & metabolism · 2022
Non-randomized trial · 12 results
- Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials.
Blonde L · Diabetes, obesity & metabolism · 2017
Non-randomized trial · 6 results
- Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L.
Blonde L · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
Non-randomized trial · 3 results
- Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis.
Yao J · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023
Non-randomized trial · 2 results
- Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial.
Iizuka K · Diabetes, obesity & metabolism · 2021
Non-randomized trial · 6 results
- Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials.
Yabe D · Journal of diabetes and its complications · 2016
Non-randomized trial · 5 results
- Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials.
Haluzík M · Diabetes, obesity & metabolism · 2024
Non-randomized trial · 2 results
- iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trial.
Yabe D · Journal of diabetes investigation · 2021
Non-randomized trial · 2 results
- Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes.
Quast DR · Diabetes, obesity & metabolism · 2021
Non-randomized trial · 12 results
- Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring.
Bergenstal RM · Diabetes/metabolism research and reviews · 2017
Non-randomized trial · 5 results
- A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes.
Barrientos-Pérez M · Pediatric diabetes · 2022
Non-randomized trial · 13 results
- Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L · Diabetes, obesity & metabolism · 2018
Non-randomized trial · 8 results
- Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
Davies MJ · Diabetes, obesity & metabolism · 2017
Non-randomized trial · 5 results
- Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes.
Meier JJ · Diabetes, obesity & metabolism · 2020
Non-randomized trial · 8 results
- Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia.
Aronson R · Diabetes, obesity & metabolism · 2019
Non-randomized trial · 1 result
- Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone.
Trujillo JM · Diabetes, obesity & metabolism · 2018
Non-randomized trial · 1 result
- Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes.
Handelsman Y · Journal of diabetes and its complications · 2019
Non-randomized trial · 1 result
- More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.
Frias J · Diabetes, obesity & metabolism · 2018
Non-randomized trial · 6 results
- iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L.
Niemoeller E · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018
Non-randomized trial · 9 results
- Effect of lixisenatide on liquid gastric emptying in type 2 diabetes - Implications for the use of GLP-1 receptor agonists before procedures.
Kovoor JG · Journal of diabetes and its complications · 2024
Non-randomized trial · 1 result
- Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan-L trial.
Giorgino F · Diabetes, obesity & metabolism · 2019
Non-randomized trial · 4 results
- Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study.
Meier JJ · Diabetes, obesity & metabolism · 2017
Non-randomized trial · 4 results
- Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.
Terauchi Y · Diabetes, obesity & metabolism · 2020
Non-randomized trial · 4 results
- Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis.
Ahrén B · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2016
Non-randomized trial · 3 results
- Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.
Liu F · Journal of diabetes investigation · 2021
Non-randomized trial · 8 results
- Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.
Davidson JA · Diabetic medicine : a journal of the British Diabetic Association · 2020
Non-randomized trial · 4 results
- Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.
Blonde L · Advances in therapy · 2019
Non-randomized trial · 6 results
- Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
Dailey G · BMJ open diabetes research & care · 2019
Non-randomized trial · 8 results
- Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements.
Sugimoto DH · Diabetes, obesity & metabolism · 2018
Non-randomized trial · 6 results
- Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan-O-AP and LixiLan-L-CN.
Ni J · Diabetes, obesity & metabolism · 2026
Non-randomized trial · 5 results
- Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials.
Eto K · Diabetology & metabolic syndrome · 2015
Observational study · 5 results
- Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies.
Feng W · BMJ open diabetes research & care · 2021
Observational study · 1 result
- Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus.
Bae JH · Diabetes & metabolism journal · 2020
Observational study · 3 results
- Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials.
Raccah D · Journal of diabetes and its complications · 2014
Observational study · 3 results
- Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.
Yang W · Diabetes, obesity & metabolism · 2024
Observational study · 3 results
- Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits.
Sudo M · Atherosclerosis · 2017
Animal study (in vivo) · rabbit · 7 results
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
Hunter K · BMC neuroscience · 2012
Animal study (in vivo) · 8 results
- Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.
Hernández C · Diabetes · 2016
Animal study (in vivo) · mouse · 7 results
- Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Liu W · Neuroscience · 2015
Animal study (in vivo) · mouse · 10 results